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Abstract
Background: Protein aggregates containing alpha-synuclein, beta-amyloid and hyperphosphorylated tau are
commonly found during neurodegenerative processes which is often accompanied by the impairment of
mitochondrial complex I respiratory chain and dysfunction of cellular systems of protein degradation. In view of
this, we aimed to develop an in vitro model to study protein aggregation associated to neurodegenerative diseases
using cultured cells from hippocampus, locus coeruleus and substantia nigra of newborn Lewis rats exposed to 0.5,
1, 10 and 25 nM of rotenone, which is an agricultural pesticide, for 48 hours.
Results: We demonstrated that the proportion of cells in culture is approximately the same as found in the brain
nuclei they were extracted from. Rotenone at 0.5 nM was able to induce alpha-synuclein and beta amyloid
aggregation, as well as increased hyperphosphorylation of tau, although high concentrations of this pesticide (over
1 nM) lead cells to death before protein aggregation. We also demonstrated that the 14kDa isoform of alpha-
synuclein is not present in newborn Lewis rats.
Conclusion: Rotenone exposure may lead to constitutive protein aggregation in vitro, which may be of relevance
to study the mechanisms involved in idiopathic neurodegeneration.
Background
Intra and extracellular accumulation of protein aggregates
distributed throughout the central nervous system are
hallmarks of neurodegenerative diseases like Parkinson’s
(PD) and Alzheimer’s (AD) [1] as well as are present in
the senile brain [2].
Intracellular insoluble inclusions containing the alpha-
synuclein protein, called Lewy bodies are commonly
found in the brainstem, cerebellum, hypothalamus and
autonomic nervous system of patients with PD, Lewy
Body dementia, multiple system atrophy and other synu-
cleinopathies [3-7].
Extracellular deposition of beta-amyloid peptide,
derived from the abnormal cleavage of amyloid precur-
sor protein, and intracellular neurofibrillary tangles of
hyperphosphorylated tau protein are features of the hip-
pocampus, cerebellum, locus coeruleus and cerebral cor-
tex [8] of healthy elderly individuals [9] and patients
with AD and other senile dementias [10].
Another common characteristic of neurodegenerative
disorders is the impairment of mitochondrial complex I
respiratory which may lead to in vivo protein aggrega-
tion [11].
In view of this, the present study aims to develop a
method of in vitro aggregation of alpha-synuclein,
hyperphosphorylated tau and beta-amyloid in cultured
cells from the hippocampus, substantia nigra and locus
coeruleus using treatment with rotenone, which is a nat-
ural pesticide and specific inhibitor of mitochondrial
NADH dehydrogenase within complex I of the respira-
tory chain leading to increase in oxidative stress possibly
mimicking what occurs during the ageing process
[12,13]. The most characterized effects of rotenone is on
mitochondrial complex I, however this compound is
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lipophilic being able to cross the cells membrane and to
inhibit the proteasome [14], promote dysfunction in
GAPDH [15] and interact also with glial cells [16].
Methods
All procedures were performed in accordance to the
institutional committee for animal care of the School of
Medicine, University of Sao Paulo (#0659/08).
Cell culture
Methodology employed for cell culture was a modifica-
tion of the previously described protocol [17]. Briefly,
neonatal Lewis rats had their brains dissected and the
areas containing hippocampus, locus coeruleus and sub-
stantia nigra were excised. After dissection, blood and
epithelial cells were removed in sterile cold solution
consisting of NaCl 120 mM, KCl 5 mM, KH2PO4 1.2
mM, MgSO4 1.2 mM, NaHCO3 25 mM, glucose 13
mM, pH 7.22. Subsequently, the tissues were cut into
small pieces using a scissors and incubated with 0.05%
trypsin (Gibco) at 37°C for 40 minutes in a water bath
kept under agitation. Then, trypsin inhibitor (0.006%,
Gibco) was added and the cells were mechanically disso-
ciated using a Pasteur pipette, after the total decoupling
the cell solution was centrifuged at 300 g for 5 minutes.
The supernatant was discarded and cells were resus-
pended in Neurobasal A medium (Gibco) supplemented
with Glutamax (Gibco) 0.25 mM, B27 (Gibco) 2%,
L-Glutamine (Sigma) 0.25 mM and Gentamicin (Gibco)
40 mg/l.
Cells were plated into either 8-well glass slides or 35
mm petri dishes (Nunc), at the concentration of 1800
cels/mm2. Plates were treated the day before with poly-
D-lysine 10 μg/ml (Sigma), and with fetal bovine serum
10% (Gibco) for 2 hours before plating the cells to facili-
tate adhesion. Cultures were kept in a humidified incu-
bator with 5% CO2 at 37°C for nine days. Culture
medium was changed three hours after plating the cells
and every three days of cultivation.
Cell culture characterization
Cell cultures were washed in PBS, fixed in 50% metha-
nol and 50% acetone for 10 minutes at -20°C, permeabi-
lized with PBS containing 0.2% Triton for 30 minutes at
room temperature. Unspecific binding sites were
blocked with PBS containing 2% NGS (Vector Labora-
tories), 0.2% Triton and 4% bovine serum albumin
(BSA, Sigma) for 30 minutes at room temperature.
Cells from substantia nigra and locus coeruleus were
incubated with mouse polyclonal antibody against tyro-
sine hydroxylase (1/3000, Sigma) for 24 hours at 4°C,
followed by incubation with anti-mouse immunoglobu-
lin conjugated to FITC (Jackson, 1/120) for 45 minutes
at room temperature protected from light. Hippocampal
cultures were subjected to MAP2 immunolabeling
(1/1000, Sigma) also at 4°C overnight followed by incu-
bation with FITC-conjugated secondary antibody in
order to identify the neurons present in cultures.
The slides were mounted with mounting medium con-
taining DAPI (4’,6-diamidino-2-phenylindole, Vector
Laboratories) to visualize cell nuclei. Immunolabeled
cells were analyzed using a fluorescence microscope
(Zeiss) equipped with appropriated filters using a 40×
lens. Quantification was done by comparing images
taken of 16 fields of culture plate using filters to visua-
lize the label generated by FITC and DAPI. Cell culture
characterization was repeated twice.
Exposure to Rotenone
Rotenone (Sigma, USA) was prepared with DMSO
(Sigma, USA) (stock solution of 1 mM) and diluted in
culture medium applied to cell cultures from hippocam-
pus, locus coeruleus and substantia nigra in concentra-
tions of 0.5, 1, 10 and 25 nM for 48 hours. Control
groups were exposed to less than 0.01% DMSO diluted
in culture medium. Cells were then subjected to trypan
blue staining in order to identify cell death; to immuno-
cytochemistry for identification of protein aggregates
containing hyperphosphorylated tau, alpha-synuclein
and beta-amyloid; and protein extraction for western
blot experiments.
Analysis of cell death
After exposure to rotenone, 10 μl of trypan blue stain
solution (Gibco) which stains in blue the cytoplasm of
cells with damaged plasma membrane, were added to
the culture medium of cells. Immediately after the addi-
tion of trypan blue, the cells were examined under a
microscope (Olympus) using an objective of 40× (400×
magnification) and photographed to detect stained cells.
Identification of protein aggregates through
immunocytochemistry
Cell cultures were fixed as described above and incubated
for 24 hours at 4°C with either a mouse polyclonal anti-
serum against alpha-synuclein (Abcam, 4D6, Ab1903), or
rabbit polyclonal antiserum against hyperphosphorylated
tau (Sigma, Ser 199/202, T6819) or beta amyloid peptide
(Abcam, Ab14220), the three antibodies were diluted
1/1000 in PBS containing 0.3% Triton X-100 (Sigma) and
0.5% BSA (Sigma). Cells were washed in PBS and incu-
bated with biotinylated goat anti-rabbit or anti-mouse
immunoglobulin both diluted 1/200 (Vector, USA) for
2 hours at room temperature. Cells were washed in PBS
and incubated with an avidin-biotin peroxidase complex
(both diluted 1/120, Vectastain, Vector) for 2 hours.
Immunoreactivity was visualized after 10 minutes of
reaction with 3-3’-diaminobenzidine tetrahydrochloride
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(DAB, Sigma) as a chromogen and H2O2 (0.01%, v/v,
Sigma).
The occupied area (μm2) of beta amyloid peptide
immunoreactivity in the hippocampus cultures was cal-
culated by means of a KS 400 image analyzer (Kontron,
Zeiss, Germany) linked to a CCD 72 camera (Dage;
MTI, Michigan City, Ind, USA) mounted on a Zeiss
microscope (40× objective). Nine randomly chosen fields
were considered for the quantification. The procedures
have been described in detail elsewhere [18].
Western blot analysis of protein aggregation
Cultured cells were homogenized in PBS, pH 7.4, con-
taining 1% NP40, 0.5% sodium deoxycholate, 1%SDS,
1 mM EDTA, 1 mM EGTA and 1% protease inhibitor
cocktail (Sigma). After centrifugation at 14000 rpm for
20 minutes, the resulting supernatant was fractionated
by SDS-PAGE (10 μg of protein/lane) using a 12% tris-
HCl gel at 100V for 1 h. Proteins were transferred to
nitrocellulose membrane for 1 h at 100V.
Blots were incubated in blocking solution containing
5% milk/TBS-T during 1 h at room temperature fol-
lowed by incubation with primary antibodies against
alpha-synuclein (Abcam, 4D6, Ab1903) or hyperpho-
sphorylated tau (Sigma, Ser 199/202, T6819) both were
diluted 1/1000 in solution containing 3% milk/TBS-T,
overnight at 4°C.
Horseradish peroxidase-conjugated secondary antibody
incubations were performed at room temperature for
1 h with antibody anti-mouse 1/6000 (Amersham) or
anti-rabbit 1/10000 (Amersham).
Development was done after 5-minute incubation with
enhanced chemiluminescence reagent (Millipore) and
exposure of membranes to ECL sensitive films (Hyper-
film ECL, Amersham Biosciences). After development,
blots were incubated with anti-beta-actin antibody
1/1000 (Santa cruz, C4, sc-47778) during 1 h at room
temperature, followed by horseradish peroxidase conju-
gated secondary antibody anti-mouse (Amersham)
diluted 1/6000 for 1 hour also at room temperature and
developed as previously described.
Density normalization was done by dividing the density
of the bands relative to proteins of interest by beta-actin
value. Films were quantified by optical densitometry
using a system of image analysis (Imaging Research Inc.,
Canada, model M4/SK/ALU).
All the analyses were made using protein samples
from control and treated cells that were fractionated in
a same gel and transferred to a single membrane which
was incubated with the antibody solution.
The presence of alpha-synuclein isoforms was con-
firmed in neonate and adult (6 months old) Wistar and
Lewis rats. This was performed because the isoform of
14kDa did not appear in cultured cells from Lewis
newborn rats. To this end, rats were euthanized and had
their brains excised instantly to protein extraction of
substantia nigra which was subjected to the same wes-
tern blot method described previously for cell culture.
In addition to the antibody from Abcam, an immuno-
globulin against alfa-synuclein from Santa Cruz Biotech-
nology (1/500; cat. 7011R) was employed to confirm the
pattern of isoforms present in neonates and adults. An
assay of adsorption was performed by adding specific
blocking peptide (1/100, Santa Cruz; cat. 7011P) to the
solution containing the antibodies to confirm their
specificity.
All the antibodies used in the present study were
tested for specificity. In the case of immunocytochem-
istry it was done by incubating the sections with the
secondary antibody only, and for western blot the con-
trol of specificity was tested in the presence of the
blocking peptide. Furthermore, the antibodies are com-
mercially available, their specificity are warranted by
the manufacturer as well as they have been tested by
other authors [19-21].
Statistical analysis
Results were analyzed by unpaired Student’s T test
accessed through GraphPad Prism (GraphPad Software
Inc., version 4.00, CA). A p-value ≤ 0.05 was considered
to indicate statistically significant differences. Data are
expressed as mean ± standard deviation (SD).
Results
Cell culture characterization
Quantification of cell cultures from the locus coeruleus
and substantia nigra showed that 53% and 44%, respec-
tively, of these cells expressed the enzyme tyrosine
hydroxylase, essential for the synthesis of catechola-
mines (Table 1). Hippocampal cultures presented 53%
of neurons labeled by MAP2 antibody (Table 1). This
reveals that the cultures were suitable for studying sub-
stantia nigra, locus coeruleus and hippocampus cells.
Effect of Rotenone on cell viability
Rotenone promoted cell death in a dose-dependent
manner in cultures of hippocampus, substantia nigra
Table 1 Cell culture characterization
DAPI TH or MAP2 % TH or MAP2 positive cells
Locus coeruleus 656 349 53.20
Substantia nigra 857 377 43.99
Hippocampus 1711 909 53.1
Quantification of the percentage of cells immunopositive to tyrosine
hydroxylase (TH) or microtubule-associated protein 2 (MAP2, Hippocampus) in
relation to the total number of cells, indicated by DAPI, in cells cultures of
locus coeruleus, substantia nigra and hippocampus. Count was performed in
16 fields of each culture plate of a total of 4 plates per experiment.
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Figure 1 Analysis of rotenone toxicity. Photomicrographs illustrating the appearance of hippocampal cells treated with 0.5 nM (A), 1 nM (B)
and 10 nM (C) of rotenone after addition of trypan blue in cell culture medium. Cells stained in blue (arrows) are under death process. Scale bar
= 50 μm. Experiment was repeated three times. Cells from substantia nigra and locus coeruleus exhibited the same pattern of sensitivity.
Figure 2 Alpha-synuclein isoforms. Western blot illustrating the isoforms of alpha-synuclein present in the substantia nigra of adult and
newborn Wistar and Lewis rats using antibody from Abcam (A) and Santa Cruz (B), confirming the absence of the 14 kDa isoform of alpha-
synuclein in neonate Lewis rats. The antibody from Abcam showed 3 isoforms of alpha-synuclein (90 kDa, 40 kDa and 14 kDa). Antibodies
specificity was demonstrated by adding blocking peptide to the solution containing antibodies, which prevented the label of bands
corresponding specifically to alpha-synuclein (C).
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and locus coeruleus. Rotenone at 0.5 nM seems not to
be toxic to the hippocampal cells (Figure 1A). Incuba-
tion with 1 nM of rotenone during 48 h stained a few
cells in blue (Figure 1B), however 10 nM of rotenone
promoted a massive cell staining with trypan blue
(Figure 1C). Cell cultures from substantia nigra and
locus coeruleus exhibited the same pattern of sensitivity
of hippocampal cells (data not shown).
Figure 3 Aggregation of alpha-synuclein after rotenone
exposure. Photomicrographs illustrating the immunoreactivity of
alpha-synuclein in cultured cells of the locus coeruleus exposed to
DMSO (A) or 0.5 nM rotenone (B) and hippocampal cells exposed to
1 nM of rotenone (C) for 48 hours. Arrows indicate cells with dense
cytoplasm aggregates of alpha-synuclein. Arrowheads indicate sites
of alpha-synuclein aggregation (detail in B). Cells were
counterstained with hematoxylin (purple) after immunoreaction.
Scale bar = 50 μm.
Figure 4 Quantification of alpha-synuclein aggregation after
rotenone exposure. Expression of alpha-synuclein isoforms of 90
kDa and 40 kDa in cell cultures of substantia nigra following
incubation with DMSO or 0.5 nM of rotenone during 48 h.
Normalization was performed by beta-actin (43 kDa) signal. Data are
shown as percent of control (DMSO) ± S.D. * p < 0.05 as compared
to control (DMSO), according to Student’s t-test. The experiment
was repeated twice, which were run in triplicates.
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Presence of alpha-synuclein isoforms in newborn
Lewis rats
The presence of alpha-synuclein isoforms was analyzed
in newborn and adult Wistar and Lewis rats because
during pilot experiments the 14 kDa isoform never
appeared in cultured cells from newborn Lewis rats.
Figure 2A shows the pattern of isoforms labeling in
newborn and adult rats from Wistar and Lewis strains
using the antibody from Abcam. This confirms the
absence of 14 kDa isoform in neonate Lewis rats and its
presence in neonatal Wistar and adult rats of both
strains. The isoforms of 40 kDa and 90 kDa are present
in all ages and strains. Adult rats showed an additional
band of 34 kDa (Figure 2A).
The same pattern of alpha-synuclein isoforms labeling
was observed in neonate and adult rats when the anti-
body from santa cruz was employed (Figure 2B). The
specificity of antibodies was demonstrated by the
absence of labeling when incubating the antibodies with
blocking peptide (Figure 2C).
Alpha-synuclein protein aggregates
Immunocytochemical staining using anti-alpha-synuclein
antibody revealed that rotenone at 0.5 nM or 1 nM pro-
moted aggregation of alpha-synuclein in cell bodies and
extensions of the locus coeruleus and hippocampus as
compared to DMSO-exposed cells (Figure 3). Besides
the protein aggregation, exposure of hippocampal cells
to 1 nM of rotenone promoted apparent retraction of
neuronal processes as well as reduced the total number
of cells.
Western blot experiments were conducted to confirm
and quantify alpha-synuclein aggregation in substantia
nigra cells. In that assay there were two specific bands
corresponding to alpha-synuclein one of 90 kDa and
another of 40 kDa, which were up-regulated by 25% and
400%, respectively, following 0.5 nM of rotenone as
compared to DMSO-exposed cells (Figure 4).
Hyperphosphorylation of tau
Cells from the hippocampus were stained with anti-
hyperphosphorylated tau antibody demonstrated that 0.5
nM of rotenone also promotes increase in hyperpho-
sphorylation of tau protein in cell body and extensions
(Figure 5). Densitometric analysis of the immunoblots
corroborate with immunocytochemical experiments
showing that isoforms of hiperphosphorylated tau of 52
and 130 kDa increase their expression demonstrating
possibly the hyperphosphorylated tau in hippocampal
cells culture after exposure to 0.5 nM of rotenone for
48 hours (Figure 6). The 230 kDa isoform showed an
unexpected significant decrease in expression, which
may reveal that, at this level of hyperphosphorylation,
tau is not aggregated yet.
Identification of beta-amyloid protein aggregates
The analysis of beta-amyloid aggregation was done by
immunocytochemistry which demonstrates that the
exposure to 1 nM of rotenone was effective in develop-
ing protein aggregates containing that peptide as com-
pared to cells exposed to DMSO (Figures 7A and 7B).
Higher concentrations of rotenone (10 and 25 nM)
Figure 5 Increased hyperphosphorylation of tau after rotenone exposure. Photomicrographs illustrating the immunoreactivity of
hyperphosphorylated tau in cultured cells of hipoccampus exposed to DMSO (A) or 0.5 nM of rotenone (B) for 48 hours. Arrows indicate sites of
hyperphosphorylated tau, possibly aggregated, distributed throughout cytoplasm and neurites. Scale bar = 50 μm.
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promoted nuclear retraction and fragmentation, as well
as decrease in cell extensions (Figures 7C and 7D)
demonstrating that high concentrations of the pesticide
probably leads cells to death before the aggregation of
beta-amyloid.
Quantification of area occupied by beta-amyloid imu-
nopositive aggregates showed a significant increase after
exposure to 0.5 nM of rotenone for 48 hours (13.12 ±
1.12) as compared to the control (2.39 ± 0.43) (Figure 8).
Discussion
To our knowledge this is the first report of in vitro pro-
tein aggregation promoted by the inhibition of mito-
chondrial respiratory chain complex I, these findings are
of special interest for studying proteins involved in neu-
rodegeneration such as alpha-synuclein, hyperpho-
sphorylated tau and beta-amyloid.
High concentrations of rotenone (over 1 nM) lead to cell
death prior to protein aggregation as demonstrated by try-
pan blue stain and amyloid beta immunocytochemistry
independently of the region studied. Rotenone is an
inhibitory drug of the mitochondrial respiratory chain
complex I. However, low concentration of this com-
pound (0.5 and 1 nM) is able to promote constitutive
protein aggregation.
Many studies have employed in vivo and in vitro mod-
els to evaluate the neurodegeneration process. These
models of neurodegeneration may involve the use of
drugs such as 6-hydroxydopamine (6-OHDA), 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rote-
none [22], or overexpression of mutant genes in rats,
mice and cell lineages [23-26]. Although these models
are relevant to understand some aspects involved neuro-
degeneration, there is still lack of information about the
events that cause constitutive protein aggregation and
its role during the neurodegenerative processes. Recently
De-Paula and colleagues [27] described that the inhibi-
tion of phospholipase A2 led to hyperphosphorylation of
tau in primary cell culture, but the aggregation of other
proteins such as alpha-synuclein and beta amyloid was
not analyzed.
The use of primary cell culture, including neurons and
glia, approximates the in vitro model and the physiologi-
cal situation encountered in the brain. Recent evidences
showed that dopaminergic death may be preceded by
glial disfunction [28,29], as well as the interaction
between neurons and astrocytes is of relevance to the
course of neurodegeneration [30]. In view of this, we
believe that the model using neurons and glial cells are
more related to the real neuropathology than studying
purified cell cultures.
The present study demonstrate that there is protein
aggregation in condition of mitochondrial stress and
proteasome inhibition which is a common feature
Figure 6 Quantification of hyperphosphorylated tau after
rotenone exposure. Illustrative images of the pattern of bands
corresponding to hyperphosphorylated tau in hippocampal cells
exposed to 0.5 nM of rotenone or DMSO for 48 hours (A). The 230
kDa bands are considered the insoluble fraction of
hyperphosphorylated tau, which seems to be reduced after
rotenone (B), the 130 kDa bands are considered as oligomers of
hyperphosphorylated tau (C) and 52-kDa bands as monomers of
hyperphosphorylated tau (D), which are increased after prolonged
exposure to low concentration of rotenone. Normalization was
performed by beta-actin (43 kDa) signal. Values are shown as
percentage of control (DMSO) ± S.D. * p < 0.05 as compared to
control (DMSO), according to Student’s t-test. The experiment was
repeated twice, which were run in triplicates.
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encountered during aging [31]. Thus, our model has
some advantages over the genetic and transfection mod-
els since the aggregation is mainly sporadic and formed
by constitutive proteins, similar to what occurs during
ageing and neurodegeneration.
To validate our study we performed an assay to char-
acterize the presence of alpha-synuclein in neonatal and
adult rats. In this study we demonstrated that the iso-
form of 14 kDa of alpha-synuclein, which is the most
studied isoform of this protein, is not present in neona-
tal Lewis rats but is expressed in the adult age. Since
cultures were made using newborn Lewis rats there was
not label of the 14 kDa isoform alpha-synuclein in
aggregation studies. The use of Lewis rats in our experi-
ments was important because of their exclusive suscept-
ibility to form protein aggregates after treatment with
rotenone in in vivo experiments [32,33].
Rotenone was able to induce alpha-synuclein aggrega-
tion, which is of interest for studying neurodegeneration
Figure 7 Aggregation of beta-amyloid peptide after rotenone exposure. Photomicrographs of cultured hippocampal cells exposed to DMSO
(A) or rotenone at concentrations of 1 nM (B), 10 nM (C) and 25 nM (D) for 48 hours, illustrating the profile of beta-amyloid immunoreactivity.
Arrows indicate the aggregates (B). Rotenone at high concentrations promoted intense cell death demonstrated by the fragmented and retracted
nuclei (C and D), there is no evidence of beta-amiloid aggregation. Nuclei were stained with hematoxylin. Scale bar = 50 μm.
Figure 8 Quantification of beta-amyloid aggregation after
rotenone exposure. Area occupied by beta-amyloid
immunopositive aggregates in hippocampal cells exposed to 1 nM
of rotenone during 48 h. Values are shown as mean±SD ***p <
0.0001 as compared to control cells (culture medium) from the
same strain according to Student’s t-test. The experiment was
repeated twice.
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associated to protein aggregation. Not only the aggrega-
tion itself is related to neurodegeneration, the imbalance
of neurotransmission may trigger neurodegenerative
mechanisms, evidences indicate that alpha-synuclein is
encountered in association with the presynaptic vesicle
pool [34] and the aberrant association between alpha-
synuclein and rab proteins [35] may be of relevance in
the study of cellular stress that leads to neurodegenara-
tive disorders.
Hyperphosphorylation of tau protein is a condition
that disrupts the intracellular trafficking impairing neu-
rotransmission in association with formation of intracel-
lular inclusion of paired helical filaments. In the present
study we demonstrated that rotenone may be involved
in hyperphosphorylation of tau protein as demonstrated
by the increase in optical density of 52 kDa subunit.
The fraction of 130 kDa is increased in rotenone-treated
cells demonstrating a possible mechanism of aggregation
that occurs in low concentrations of rotenone. The
130 kDa band may correspond to small aggregates
(dimerization/trimerization) of hyperphosphorylated tau,
as previously demonstrated [36,37].The presence of tau
hyperphosphorylated in control groups is apparently
normal in neonatal rats and has been described by
Goedert and colleagues [38].
Beta-amyloid plaques were found in cells from hippo-
campus after incubation during 48 h with rotenone.
High concentrations of the drug is toxic leading to cell
death before protein aggregation, which is devoid to the
high toxicity. Furthermore, endogenous increase of amy-
loid beta peptide production preceeds hyperphosphory-
lation of tau [39], which may be of interest to evaluate
the mechanism of protein aggregation.
Besides the well known effects of rotenone in inhibit-
ing mitochondrial complex I, the pesticide is also able
to impair protein degradation by interfering with the
ubiquitin-proteasome-system [40], in view of this the
aggregation seen in the present study may be also in
response to the deficit of the cellular systems of protein
degradation in addition to the increase in oxidative
stress. Actually Branco and co-workers demonstrated
the cross-talk between mitochondria and proteasome
during the pathogenesis of Parkinson’s disease [41]. The
effect of rotenone over the impairment of the protea-
some is being conducted as a parallel study in our
laboratory.
Conclusions
In conclusion this study demonstrated a new method to
study constitutive protein aggregation in vitro by the
exposure of neonatal cultured cells of Lewis rats to low
concentrations of rotenone, which may be of relevance
to understand the mechanisms that lead to idiopathic
neurodegeneration.
Acknowledgements
We thank Edilaine Tampellini Santos and Livia Polichiso for their support
during antibodies standardizing for immunohistochemistry and identification
of aggregates in rat cells. This study was supported by research grants from
FAPESP (2008/04480-9) and CNPq (472042/2008-4). R.S.C., T.Q.M. and S.A.M.
received fellowships from FAPESP (2008/04655-3; 2009/02345-0 and 2009/
00010-0, respectively).
Authors’ contributions
RSC carried out cell culture characterization, cell death assay,
immunocytochemistry of alpha-synuclein and western blot experiments.
TQM performed beta-amyloid immunocytochemistry in cultured cells made
by herself. SAM carried out cell cultures and tau immunocytochemistry.
MFRF conceived of the study, designed and coordinated the experiments.
All authors analyzed the results, participated of manuscript draft, read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 June 2010 Accepted: 10 November 2010
Published: 10 November 2010
References
1. Ross CA, Poirier MA: Opinion: What is the role of protein aggregation in
neurodegeneration? Nature reviews 2005, 6(11):891-898.
2. Dayan AD: Quantitative histological studies on the aged human brain. I.
Senile plaques and neurofibrillary tangles in “normal” patients. Acta
neuropathologica 1970, 16(2):85-94.
3. Jager W, Bethlem J: The distribution of Lewy bodies in the central and
autonomic nervous systems in idiopathic paralysis agitans. J Neurol
Neurosurg Psychiatry 1960, 23:283-290.
4. Ohama E, Ikuta F: Parkinson’s disease: distribution of Lewy bodies and
monoamine neuron system. Acta neuropathologica 1976, 34(4):311-319.
5. Oyanagi K, Wakabayashi K, Ohama E, Takeda S, Horikawa Y, Morita T, Ikuta F:
Lewy bodies in the lower sacral parasympathetic neurons of a patient
with Parkinson’s disease. Acta neuropathologica 1990, 80(5):558-559.
6. Kakita A, Takahashi H, Homma Y, Ikuta F: Lewy bodies in the cerebellar
dentate nucleus of a patient with Parkinson’s disease. Pathology
international 1994, 44(12):878-880.
7. Wakabayashi K, Takahashi H: Neuropathology of autonomic nervous
system in Parkinson’s disease. Eur Neurol 1997, 38:2-7.
8. Takahashi RH, Nam EE, Edgar M, Gouras GK: Alzheimer beta-amyloid
peptides: normal and abnormal localization. Histology and histopathology
2002, 17(1):239-246.
9. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O,
Szoeke C, Ourselin S, Ames D, et al: Beta-amyloid burden in the temporal
neocortex is related to hippocampal atrophy in elderly subjects without
dementia. Neurology 2010, 74(2):121-127.
10. Jellinger KA: Recent advances in our understanding of
neurodegeneration. J Neural Transm 2009, 116(9):1111-1162.
11. Sherer TB, Kim JH, Betarbet R, Greenamyre JT: Subcutaneous rotenone
exposure causes highly selective dopaminergic degeneration and alpha-
synuclein aggregation. Experimental neurology 2003, 179(1):9-16.
12. Dukes AA, Korwek KM, Hastings TG: The effect of endogenous dopamine
in rotenone-induced toxicity in PC12 cells. Antioxidants & redox signaling
2005, 7(5-6):630-638.
13. Sherer TB, Betarbet R, Kim JH, Greenamyre JT: Selective microglial
activation in the rat rotenone model of Parkinson’s disease. Neuroscience
letters 2003, 341(2):87-90.
14. Chou AP, Li S, Fitzmaurice AG, Bronstein JM: Mechanisms of
rotenone-induced proteasome inhibition. Neurotoxicology 2010,
31(4):367-372.
15. Huang J, Hao L, Xiong N, Cao X, Liang Z, Sun S, Wang T: Involvement of
glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell
apoptosis: relevance to protein misfolding and aggregation. Brain
research 2009, 1279:1-8.
16. Silva JM, Wong A, Carelli V, Cortopassi GA: Inhibition of mitochondrial
function induces an integrated stress response in oligodendroglia.
Neurobiology of disease 2009, 34(2):357-365.
Chaves et al. BMC Neuroscience 2010, 11:144
http://www.biomedcentral.com/1471-2202/11/144
Page 9 of 10
17. Kivell BM, McDonald FJ, Miller JH: Method for serum-free culture of late
fetal and early postnatal rat brainstem neurons. Brain research 2001,
6(3):91-99.
18. Zoli M, Zini I, Agnati L, Guidolin D, Ferraguti F, Fuxe K: Aspects of neuronal
plasticity in the central nervous system. I. Computer-assisted image
analysis methods. Neurochem Int 1990, 16:383-418.
19. Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS: The
cochaperone BAG2 sweeps paired helical filament- insoluble tau from
the microtubule. J Neurosci 2009, 29(7):2151-2161.
20. Marksteiner J, Humpel C: Beta-amyloid expression, release and
extracellular deposition in aged rat brain slices. Molecular psychiatry 2008,
13(10):939-952.
21. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L: Wild type alpha-synuclein is
degraded by chaperone-mediated autophagy and macroautophagy in
neuronal cells. The Journal of biological chemistry 2008,
283(35):23542-23556.
22. Schmidt WJ, Alam M: Controversies on new animal models of Parkinson’s
disease pro and con: the rotenone model of Parkinson’s disease (PD).
Journal of neural transmission 2006, 70:273-276.
23. Gotz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P,
Chen F: Transgenic animal models of Alzheimer’s disease and related
disorders: histopathology, behavior and therapy. Molecular psychiatry
2004, 9(7):664-683.
24. Hattori N, Sato S: Animal models of Parkinson’s disease: similarities and
differences between the disease and models. Neuropathology 2007,
27(5):479-483.
25. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ: Formation and removal of alpha-
synuclein aggregates in cells exposed to mitochondrial inhibitors. The
Journal of biological chemistry 2002, 277(7):5411-5417.
26. Schule B, Pera RA, Langston JW: Can cellular models revolutionize drug
discovery in Parkinson’s disease? Biochim Biophys Acta 2009,
1792(11):1043-1051.
27. De-Paula VJ, Schaeffer EL, Talib LL, Gattaz WF, Forlenza OV: Inhibition of
phospholipase A2 increases tau phosphorylation at Ser214 in embryonic
rat hippocampal neurons. Prostaglandins, leukotrienes, and essential fatty
acids 2010, 82(1):57-60.
28. Hirsch EC, Hunot S: Neuroinflammation in Parkinson’s disease: a target
for neuroprotection? Lancet neurology 2009, 8(4):382-397.
29. Tansey MG, Goldberg MS: Neuroinflammation in Parkinson’s disease: its
role in neuronal death and implications for therapeutic intervention.
Neurobiology of disease 2010, 37(3):510-518.
30. Mullett SJ, Hinkle DA: DJ-1 knock-down in astrocytes impairs astrocyte-
mediated neuroprotection against rotenone. Neurobiology of disease 2009,
33(1):28-36.
31. Boveris A, Navarro A: Brain mitochondrial dysfunction in aging. IUBMB Life
2008, 60(5):308-314.
32. Testa CM, Sherer TB, Greenamyre JT: Rotenone induces oxidative stress
and dopaminergic neuron damage in organotypic substantia nigra
cultures. Molecular Brain Research 2005, 134(1):109-118.
33. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW,
Yagi T, Matsuno-Yagi A, Greenamyre JT: Mechanism of toxicity in
rotenone models of Parkinson’s disease. J Neurosci 2003,
23(34):10756-10764.
34. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM: Synucleins are
developmentally expressed, and alpha-synuclein regulates the size of
the presynaptic vesicular pool in primary hippocampal neurons. J
Neurosci 2000, 20(9):3214-3220.
35. Dalfo E, Barrachina M, Rosa JL, Ambrosio S, Ferrer I: Abnormal alpha-
synuclein interactions with rab3a and rabphilin in diffuse Lewy body
disease. Neurobiology of disease 2004, 16(1):92-97.
36. Blard O, Frebourg T, Campion D, Lecourtois M: Inhibition of proteasome
and Shaggy/Glycogen synthase kinase-3beta kinase prevents clearance
of phosphorylated tau in Drosophila. Journal of neuroscience research
2006, 84(5):1107-1115.
37. Shelton SB, Johnson GV: Tau and HMW tau phosphorylation and
compartmentalization in apoptotic neuronal PC12 cells. Journal of
neuroscience research 2001, 66(2):203-213.
38. Goedert M, Jakes R, Crowther RA, Six J, Lubke U, Vandermeeren M, Cras P,
Trojanowski JQ, Lee VM: The abnormal phosphorylation of tau protein at
Ser-202 in Alzheimer disease recapitulates phosphorylation during
development. Proceedings of the National Academy of Sciences of the United
States of America 1993, 90(11):5066-5070.
39. Amadoro G, Corsetti V, Ciotti MT, Florenzano F, Capsoni S, Amato G,
Calissano P: Endogenous Abeta causes cell death via early tau
hyperphosphorylation. Neurobiol Aging 2009.
40. Wang XF, Li S, Chou AP, Bronstein JM: Inhibitory effects of pesticides on
proteasome activity: implication in Parkinson’s disease. Neurobiology of
disease 2006, 23(1):198-205.
41. Branco DM, Arduino DM, Esteves AR, Silva DF, Cardoso SM, Oliveira CR:
Cross-talk between mitochondria and proteasome in Parkinson’s disease
pathogenesis. Frontiers in aging neuroscience 2010, 2:17.
doi:10.1186/1471-2202-11-144
Cite this article as: Chaves et al.: Protein aggregation containing beta-
amyloid, alpha-synuclein and hyperphosphorylated tau in cultured cells
of hippocampus, substantia nigra and locus coeruleus after rotenone
exposure. BMC Neuroscience 2010 11:144.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chaves et al. BMC Neuroscience 2010, 11:144
http://www.biomedcentral.com/1471-2202/11/144
Page 10 of 10
